Boehringer Ingelheim International Gmbh

Boehringer Ingelheim (canada) Ltd.

Gilead Sciences, Inc.

Boehringer Ingelheim Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Murray D Bailey

Montse Llinas-Brunet

Teddy Halmos

Nathalie Goudreau

Elise Ghiro

Jean Rancourt

Youla S Tsantrizos

Marc-Andre Poupart

Dominik M Wernic

Anne-Marie Faucher

Dale R Cameron

Bruno Simoneau

Lee Fader

Francois Bilodeau

Rebekah J Carson

Punit R Bhardwaj

Stephen Kawai

Pasquale Forgione

Sebastien Morin

Mathieu Parisien

Carl Thibeault

Marc-André Poupart

Sylvie Goulet

Serge R Landry

Simon Surprenant

Vida J Gorys

Josee Bordeleau

Pierre Louis Beaulieu

Christiane Yoakim

Cédrickx Godbout

Martin Poirier

Julie Naud

André Giroux

Steven LaPlante

Rene Coulombe

Dale Cameron

Marc-Andr&eacute; Poupart

Olivier Lepage

Steven R Laplante

Elisia Villemure

Benoît Moreau

Gulrez Fazal

Christian Brochu

Paul John Edwards

Pierre Lavallee

Maude A Poirier

Oliver Hucke

Araz Jakalian

Ellse Ghiro

Punit K Bhardwaj

William Ogilvie

Punit-Kumar Bhardwaj

Steven Laplantea

François Bilodeau

Mélissa Leblanc

Marc-André Joly

Maude Poirier

Paul J Edwards

Sébastien Morin

Compounds of Formula (I) wherein n, m, R, R, R, R, R5 and R6 are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection. 

Cytomegalovirus inhibitor compounds

Compounds of Formula (I) wherein n, A, R, R, Rand Rare defined herein, are useful for the treatment of cytomegalovirus disease and/or infection. 

Compounds of formula I: wherein a, R, R, R, R, Rand Rare defined herein, are useful as inhibitors of HIV replication.

Inhibitors of human immunodeficiency virus replication

Compounds of formula I: wherein R, Rand Rare defined herein, are useful as inhibitors of HIV replication.

Compounds of formula (I): wherein c, X, Y, R, Rand Rare defined herein, are useful as inhibitors of HIV replication. 

Compounds of formula I: wherein c, R, R, R, R, R, Rand Rare defined herein, are useful as inhibitors of HIV replication. 

Compounds of formula (I): wherein B, X, R, L, L, L, R, Rand Rare defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.

Hepatitis C inhibitor compounds

Racemates, diastereoisomers and optical isomers of a compound of formula (I):wherein

Hepatitis C inhibitor tri-peptides

Compounds of formula (I):  wherein R, R, R, R, n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease.

Hepatitis C inhibitor dipeptide analogs

Compounds of formula (I): wherein R, R, X, R, D, and the dotted line b are as defined herein; or a pharmaceutically acceptable salt or ester thereof, are useful as inhibitors of the HCV NS3 protease.

Macrocyclic peptides active against the hepatitis C virus

Racemates, diastereolsomers and optical isomers of a compound of formula (I):wherein B is H, a Cor Caryl, Caralkyl; Het or (lower alkyl)-Het, all of which optionally substituted with Calkyl; Calkoxy; Calkanoyl; hydroxy; hydroxyalkyl; halo; haloalkyl; nitro; cyano; cyanoalkyl; amino optionally substituted with Calkyl; amido; or (lower alkyl)amide; or

Growing community of inventors

Pierrefonds, Canada

Murray D Bailey